Prosocial effects of oxytocin and clinical evidence for its therapeutic potential.

Department of Psychiatry, University of Bonn, 53105 Bonn, Germany.
Frontiers in Neuroendocrinology (Impact Factor: 7.99). 07/2011; 32(4):426-50. DOI: 10.1016/j.yfrne.2011.07.001
Source: PubMed

ABSTRACT There has been unprecedented interest in the prosocial effects of the neuropeptide oxytocin in humans over the last decade. A range of studies has demonstrated correlations between basal oxytocin levels and the strength of social and bonding behaviors both in healthy individuals and in those suffering from psychiatric disorders. Mounting evidence suggests associations between polymorphisms in the oxytocin receptor gene and prosocial behaviors and there may also be important epigenetic effects. Many studies have now reported a plethora of prosocial effects of intranasal application of oxytocin, including the domains of trust, generosity, socially reinforced learning, and emotional empathy. The main focus of this review will be to summarize human preclinical work and particularly the rapidly growing number of clinical studies which have identified important links between oxytocin and a wide range of psychiatric disorders, and have now started to directly assess its therapeutic potential.

  • Well-Being in Contemporary Society, Edited by J. H. Soraker, J.-W. van der Rijt, J. de Boer, P.-H. Wong, P. Brey, 01/2015: chapter Improving the Health Care Sector with a Happiness-Based Approach.: pages 59-71; Springer., ISBN: 978-3-319-06458-1
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mouse models of neuropsychiatric diseases provide a platform for mechanistic understanding and development of new therapies. We previously demonstrated that knockout of the mouse homolog of CNTNAP2 (contactin-associated protein-like 2), in which mutations cause cortical dysplasia and focal epilepsy (CDFE) syndrome, displays many features that parallel those of the human disorder. Because CDFE has high penetrance for autism spectrum disorder (ASD), we performed an in vivo screen for drugs that ameliorate abnormal social behavior in Cntnap2 mutant mice and found that acute administration of the neuropeptide oxytocin improved social deficits. We found a decrease in the number of oxytocin immunoreactive neurons in the paraventricular nucleus (PVN) of the hypothalamus in mutant mice and an overall decrease in brain oxytocin levels. Administration of a selective melanocortin receptor 4 agonist, which causes endogenous oxytocin release, also acutely rescued the social deficits, an effect blocked by an oxytocin antagonist. We confirmed that oxytocin neurons mediated the behavioral improvement by activating endogenous oxytocin neurons in the paraventricular hypothalamus with Designer Receptors Exclusively Activated by Designer Drugs (DREADD). Last, we showed that chronic early postnatal treatment with oxytocin led to more lasting behavioral recovery and restored oxytocin immunoreactivity in the PVN. These data demonstrate dysregulation of the oxytocin system in Cntnap2 knockout mice and suggest that there may be critical developmental windows for optimal treatment to rectify this deficit. Copyright © 2015, American Association for the Advancement of Science.
    Science translational medicine 01/2015; 7(271):271ra8. · 14.41 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The posterior pituitary neuropeptideoxytocin as one of two neurohypophyseal hormones (along with vasopressin) is an important regulator of feeding, grooming and responses to nocifensive stimuli and stress in a variety of rodents, sheep and primates, including humans. It also modulates the function of CNS structures that are significant to the regulation of behavior, social cognition and sexual behavior, such as: affiliation, including mating, pair bonding or parenting behaviors (maternal aggression for example). The CNS effects of oxytocin are regulated by gonadal steroid hormones, particularly estrogen. Oxytocin might also be involved in the etiology and expression of neuropsychiatric disorders, e.g. schizophrenia, depression or neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases.
    Magazyn Weterynaryjny. 01/2015; 24(212):654-656.


1 Download